Epizyme Inc logo

EPZM

Epizyme Inc

$1.47

Earnings Summary

Revenue
$8.7Mn
Net Profits
$-55.51Mn
Net Profit Margins
-638.28%

Highlights

Revenue:

Epizyme Inc’s revenue jumped 13.96% since last year same period to $8.7Mn in the Q1 2022. On a quarterly growth basis, Epizyme Inc has generated -24.92% fall in its revenue since last 3-months.

Net Profits:

Epizyme Inc’s net profit jumped 21.02% since last year same period to $-55.51Mn in the Q1 2022. On a quarterly growth basis, Epizyme Inc has generated -9.58% fall in its net profits since last 3-months.

Net Profit Margins:

Epizyme Inc’s net profit margin jumped 30.69% since last year same period to -638.28% in the Q1 2022. On a quarterly growth basis, Epizyme Inc has generated -45.96% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Epizyme Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.36
EPS Estimate Current Year
-0.36

Highlights

EPS Estimate Current Quarter:

Epizyme Inc’s earning per share (EPS) estimates for the current quarter stand at -0.36 - a -2.86% fall from last quarter’s estimates.

EPS Estimate Current Year:

Epizyme Inc’s earning per share (EPS) estimates for the current year stand at -0.36.

Key Ratios

Key ratios of the Epizyme Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.38
Return on Assets (ROA)
-0.39
Return on Equity (ROE)
-8.77
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Epizyme Inc’s earning per share (EPS) jumped 44.93% since last year same period to -0.38 in the Q1 2022. This indicates that the Epizyme Inc has generated 44.93% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Epizyme Inc’s return on assets (ROA) stands at -0.39.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Epizyme Inc’s return on equity (ROE) stands at -8.77.

Dividend Per Share (DPS):

Epizyme Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-0.35
-0.38
-8.57%

Company Information

Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..

Organisation
Epizyme Inc
Headquarters
Cambridge, Massachusetts, US
Employees
304
Industry
Health Technology
CEO
Robert Bazemore